Early Postoperative Intraperitoneal Chemotherapy as an Adjuvant Therapy to Surgery for Peritoneal Carcinomatosis from Gastrointestinal Cancer: Pharmacological Studies

作者: Paul H. Sugarbaker , P. Schlag , E. A. DeBruijn , W. J. Cunliffe , R. E. Mullins

DOI:

关键词:

摘要: Gastrointestinal malignancy may spread to peritoneal surfaces in the absence of lymphatic or hematogenous metastases. To treat carcinomatosis, a uniformly lethal disease process, extensive cytoreductive surgery and i.p. chemotherapy were combined. Early postoperative was instilled first few days after surgical procedure an attempt anatomic sites that would be sealed off by adhesions. Mitomycin C given on day at two doses, 10 12 mg/m2. 5-Fluorouracil 2-5 15 20 mg/kg, respectively. Median area under curve ratio i.p./i.v. 117 for 5-fluorouracil 21.6 mitomycin C. Elevated intraportal levels drug observed but not The marked pharmacokinetic advantage suggests this treatment strategy should considered clinical trial patients risk progression carcinomatosis.

参考文章(9)
William E. Hull, Rüdiger E. Port, Werner Kunz, Richard Herrmann, Bärbel Britsch, Metabolites of 5-Fluorouracil in Plasma and Urine, as Monitored by 19F Nuclear Magnetic Resonance Spectroscopy, for Patients Receiving Chemotherapy with or without Methotrexate Pretreatment Cancer Research. ,vol. 48, pp. 1680- 1688 ,(1988)
Paul H. Sugarbaker, Jerry M. Collins, Robert L. Dedrick, Charles E. Myers, James L. Speyer, Raymond W. Klecker, Portal Levels and Hepatic Clearance of 5-Fluorouracil after Intraperitoneal Administration in Humans Cancer Research. ,vol. 41, pp. 1916- 1922 ,(1981)
U.R. Tjaden, E.A. De Bruijn, R.A.M. Van Der Hoeven, C. Jol, J. Van Der Greef, H. Lingeman, Automated analysis of mitomycin C in body fluids by high-performance liquid chromatography with on-line sample pre-treatment. Journal of Chromatography B: Biomedical Sciences and Applications. ,vol. 420, pp. 53- 62 ,(1987) , 10.1016/0378-4347(87)80154-8
Paul H. Sugarbaker, Raymond W. Klecker, Fred J. Gianola, James L. Speyer, Prolonged treatment schedules with intraperitoneal 5-fluorouracil diminish the local-regional nature of drug distribution. American Journal of Clinical Oncology. ,vol. 9, pp. 1- 7 ,(1986) , 10.1097/00000421-198602000-00001
W. J. Cunliffe, P. H. Sugarbaker, Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy British Journal of Surgery. ,vol. 76, pp. 1082- 1090 ,(2005) , 10.1002/BJS.1800761030
Vincent T. DeVita, Jerry M. Collins, Alan R. Buckpitt, Robert L. Dedrick, Murray F. Brennan, Charles E. Myers, James L. Speyer, Harold Londer, Phase I and Pharmacological Studies of 5-Fluorouracil Administered Intraperitoneally Cancer Research. ,vol. 40, pp. 567- 572 ,(1980)
Douglass Ho, Gastric cancer: overview of current therapies. Seminars in Oncology. ,vol. 12, pp. 57- 62 ,(1985)